Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Stock Price Up as Sentiment Increases

January 23, 2018 - By Vivian Park

 Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Stock Price Up as Sentiment  Increases

Sentiment for Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) institutional sentiment increased to 1.43 in Q3 2017. Its up 0.26, from 1.17 in 2017Q2. The ratio is more positive, as 66 hedge funds increased or opened new equity positions, while 46 trimmed and sold stakes in Vanda Pharmaceuticals Inc. The hedge funds in our partner’s database now have: 38.89 million shares, up from 37.25 million shares in 2017Q2. Also, the number of hedge funds holding Vanda Pharmaceuticals Inc in their top 10 equity positions decreased from 3 to 2 for a decrease of 1. Sold All: 12 Reduced: 34 Increased: 45 New Position: 21.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $678.41 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

The stock increased 4.14% or $0.6 during the last trading session, reaching $15.1. About 570,209 shares traded or 5.30% up from the average. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since January 23, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on February, 21. They expect $-0.12 EPS, down 400.00 % or $0.16 from last year’s $0.04 per share. After $-0.10 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 20.00 % negative EPS growth.

Armistice Capital Llc holds 3.23% of its portfolio in Vanda Pharmaceuticals Inc. for 1.53 million shares. Palo Alto Investors Llc owns 4.16 million shares or 3.13% of their US portfolio. Moreover, Great Point Partners Llc has 1.73% invested in the company for 497,531 shares. The California-based Venbio Select Advisor Llc has invested 1.37% in the stock. University Of Notre Dame Du Lac, a Indiana-based fund reported 157,781 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 4 insider sales for $3.36 million activity.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Ratings analysis reveals 100% of Vanda Pharmaceuticals’s analysts are positive. Out of 8 Wall Street analysts rating Vanda Pharmaceuticals, 8 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $15 while the high is $26.0. The stock’s average target of $22.25 is 47.35% above today’s ($15.1) share price. VNDA was included in 21 notes of analysts from September 2, 2015. The firm earned “Buy” rating on Thursday, August 3 by Oppenheimer. JMP Securities maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, March 9 with “Market Outperform” rating. Oppenheimer maintained it with “Outperform” rating and $26 target in Monday, October 30 report. The rating was maintained by H.C. Wainwright on Thursday, August 3 with “Buy”. The company was maintained on Wednesday, September 2 by Piper Jaffray. The firm has “Buy” rating given on Wednesday, November 9 by Aegis Capital. The rating was maintained by JMP Securities with “Market Outperform” on Friday, August 26. On Tuesday, June 27 the stock rating was initiated by Piper Jaffray with “Buy”. Jefferies maintained the stock with “Buy” rating in Monday, September 4 report. Brean Capital initiated Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, October 21 with “Buy” rating.

Another recent and important Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news was published by which published an article titled: “This Morning’s Technical Outlook on Biotech Stocks — Moleculin Biotech, Vanda …” on January 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: